* Note: Prices are in Million (M) USD.
Description:
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $197 M
Debt : $36 M
EBITDA : $-511 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Life sciences
Industry: Biological products, (no disgnostic substances)
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 11 overlapping fiscal years (max 20).Average Free Cash Flow: $-80 M
Average Revenue: $151 M
Revenue Converted To Free Cash Flow (%): -53.2%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $35 M
Revenue 5 Years Ago (2019-12-31): $290 M
Total Growth over 5 Years: -87.9%
5-Year Revenue CAGR (Historical): -34.5%
Forward 5-Year CAGR (Tapered): -31.0%
Since historical Revenue CAGR is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $84 M
Share Count 5 Years Ago (2020-12-31): $66 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Message: Cannot calculate payout ratio because EPS is either 0 or negative.
Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 9 valid ROE years (max 20).Average ROE: -16.5%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $63
52-Week Low: $30
Threshold Price (15% Above 52-Week Low): $35
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $5,432 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
Owners' Earnings (FCF/Share, latest positive annual) (2021-12-31): $5.42
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 8 points to above Crispr Therapeutics AG (CRSP) stock.
Last 1 Years Avg PE 17.14, Fair Value PE 9, Industry Based PE 18, Risk-Free Anchored PE (25% MoS) 17.61. Based on these 4 values (after removing statistical outliers, n=3), average assigned is 14.87. The fair value of Crispr Therapeutics AG (CRSP) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
